prospect of genotyping thousands of individuals for a multitude of SNPs posed a serious practical and financial barrier for researchers.
Fortunately, nature appears to have provided a shortcut of sorts. In the last couple of years it has become increasingly clear that SNPs, which form the basis of most genetic differences between individuals, are very often in a state of linkage disequilibrium (LD) with their surrounding DNA -that is, blocks of neighboring SNPs are inherited together, effectively defining a haplotype for the corresponding region. This is great news for finding disease genes because it means a unique SNP or a unique combination of SNPs could stand in for the entire haplotype in a genetic test, making large-scale association studies much more economically feasible. But getting to this efficient stage will require a tremendous amount of initial work to build a haplotype map from which informative SNPs for each
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Gene link studies forge new collaborations
Genomes: The human genome is rapidly becoming the human genomes. Efforts are now growing to use the new data to gather information on the extent of genetic diversity, seeking insights into risk factors and susceptibility to a range of diseases.
Heather Dawes reports.
Clues from diversity: Researchers hope that analysis of genetic differences will reveal clues to disease susceptibility. Given the great potential of haplotype-based genome scans to aid our understanding of common diseases, it's not surprising that plans for a large scale project are brewing...
Significant ethical considerations
are warranted because to produce a whole genome haplotype map that includes all common haplotypes found in human populations, the project will need to draw genetic information from a diversity of ethnic groups. This is due to the fact that LD and SNP frequencies are influenced by events in population history that include bottlenecks, genetic isolation and admixture, and the extent to which haplotype structure varies between and among groups has only recently begun to be explored. A main challenge for the project will be achieving inclusiveness while avoiding the perception of exploitation, according to Ellen Wright Clayton, a member of one of the project's working groups and an expert in bioethics and law at Vanderbilt University. Community involvement is key, according to Clayton. "The driving force behind this is the recognition that science is a collaboration."
Chief among the technical issues facing the project at this stage is simply the fact that the nature of LD across the genome is variable and remains largely unknown, and the number of SNPs and population pools required for the construction of a useful, inclusive haplotype map is still unclear. According to Brooks, the methods working group set up at the July meeting is currently undertaking a broad analysis of the SNP data already available from between 10 and 50 genomic regions from a small number of population groups, looking to answer basic questions such as how best to define haplotype blocks in the first place. The plan is then to move onto a pilot project analysing SNPs from the same regions from an extended collection of 12 or 13 groups to get a clearer idea of how haplotype structure varies across populations.
Critical to these initial efforts, says Brooks, is the flurry of ongoing research into human Concurrent with the pilot efforts will be the upcoming initiation of the large scale project, which will focus at first on SNP mapping in three populations -most likely African-American, ChineseAmerican and European-American -in collaboration with longstanding partnerships between NHGRI and local community groups in the US. Eventually, according to Brooks, the findings of the pilot haplotype projects will allow informed decisions to be made about the best populations to add to the large scale project to ensure that the haplotype map being developed is informative and inclusive. While the projected timeframe is uncertain, speed is a priority, and requests for applications for the project will be issued by the NHGRI sometime this spring, with a goal of funding beginning in early fall.
In the meantime, SNP discovery and haplotype analysis continue to be hot areas of activity within the biotech community, particularly at companies such as Millenium, Celera, Genaissance and Perlegen, and high impact work on haplotype structure from biotech groups is being published (see Stephens et In contrast to the genome-wide approach planned by the public project, biotech groups oftenthough not always -focus their SNP discovery and haplotype analysis on gene loci or even particular gene families suspected of playing a role in disease or drug response.
The hope is that targeted approaches will have the potential to identify some functionally important SNPs in a relatively short term, whereas an advantage of a genome-wide effort is that it would overcome, and eventually help answer, questions regarding the functional importance of SNPs in distal regulation of genes.
While the methods and short term goals of the private groups may differ from those of public efforts, collaboration between the two communities is likely to be essential to the development of a information rich haplotype map.
Despite the considerable unknowns regarding the eventual requirements for SNP data and analysis, the chief obstacle for the haplotype map's development isn't technical, but rather financial, according to David Cox, Co-founder and Chief Scientific Officer of Perlegen Sciences. "This whole endeavor takes a lot of money, and different people in different settings are going to be finding different SNPs and different pieces of information," says Cox. "There will be ways for that information to be shared."
